{
    "organizations": [],
    "uuid": "e75aeee6e6c589edddf73d90a52614deb66ca545",
    "author": "",
    "url": "https://www.reuters.com/article/brief-menlo-therapeutics-announces-resul/brief-menlo-therapeutics-announces-results-from-phase-2-trial-of-serlopitant-for-pruritus-associated-with-atopic-dermatitis-idUSASC09V73",
    "ord_in_thread": 0,
    "title": "BRIEF-Menlo Therapeutics Announces Results From Phase 2 Trial Of Serlopitant For Pruritus Associated With Atopic Dermatitis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Menlo Therapeutics Inc:\n* MENLO THERAPEUTICS ANNOUNCES RESULTS FROM A PHASE 2 TRIAL OF SERLOPITANT FOR PRURITUS ASSOCIATED WITH ATOPIC DERMATITIS\n* ‍STUDY DID NOT MEET ITS PRIMARY OR KEY SECONDARY EFFICACY ENDPOINTS\n* ‍SERLOPITANT WAS WELL-TOLERATED IN THIS STUDY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-09T08:23:00.000+03:00",
    "crawled": "2018-04-09T08:42:03.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "menlo",
        "therapeutic",
        "inc",
        "menlo",
        "therapeutic",
        "announces",
        "result",
        "phase",
        "trial",
        "serlopitant",
        "pruritus",
        "associated",
        "atopic",
        "dermatitis",
        "meet",
        "primary",
        "key",
        "secondary",
        "efficacy",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}